DSE:RENATA

Renata PLC research

Reports on Renata PLC

Company · Initiation · 29 Oct 2026

Renata's FY2026 recovery is real, but a 10% return on equity supports BDT 146–350 a share (base 234)

Fair value BDT 146–350 (base 234) vs price 425.9 on 29-Oct-2026. FY2026 EPS rose 64% to BDT 31.76 as debt fell; DGDA price controls, a weaker taka on imported APIs and LDC/TRIPS are the risks.

Renata PLC (DSE: RENATA) is one of Bangladesh's five largest drug makers and the leader in animal health. It makes branded generics for doctors and pharmacies at home, veterinary medicines, vaccines and feed premixes for farmers, contract-manufactured products, and a growing range of generics for…

Fair value ৳146–350 · price ৳425.90 (2026-10-29)

Peer comparisons and industry research covering Renata PLC

Company · DSE:IBNSINA · Pharmaceuticals & healthcare · Analysis · 29 Oct 2026

IBN SINA Pharmaceutical: 9M FY2026 sales up 18% as the Mawna plant lifts capital work-in-progress to BDT 4.1bn, funded mostly with debt

Sales rose every year for ten years, at 4.5-24.6% a year, with steady 40-42% gross margins; selling and distribution takes 30% of revenue, so ROE fell from 24-25% to 17% in FY2025. The FY2026 cash dividend is 77%, the highest yet.

The IBN SINA Pharmaceutical Industry PLC (IPI) makes and sells allopathic ("pharma") medicines and, through its subsidiary The IBN SINA Natural Medicine Ltd., Unani, Ayurvedic and herbal products. Its fiscal year ends on 30 June: the audited FY2025 statements cover 1-Jul-2024 to 30-Jun-2025. Group revenue…

All Bangladesh research →